Literature DB >> 20811711

Blood monocytes from mammary tumor-bearing mice: early targets of tumor-induced immune suppression?

Raul Caso1, Risset Silvera, Roberto Carrio, Viyaya Iragavarapu-Charyulu, Ruben R Gonzalez-Perez, Marta Torroella-Kouri.   

Abstract

We have previously shown that peritoneal macrophages from mice bearing advanced D1-DMBA3 mammary tumors are impaired in their inflammatory functions but are not alternatively activated either and are less differentiated than the ones from normal mice. However, little is known about whether similar defects exist in their precursor stages as blood monocytes. We examined if blood monocytes from mammary tumor-bearing mice are already altered in their activation profiles before becoming macrophages and whether they correspond to inflammatory or resident monocyte subtypes. Much effort is currently devoted to reversing macrophage adverse traits in tumor hosts; as these cells reside within tissues, access is limited. Blood monocytes could be better targeted and manipulated by less invasive means. In the present study, mononuclear cells were isolated from whole blood of D1-DMBA-3 mammary tumor-bearing and normal BALB/c mice and CD115(+) monocytes were analyzed. Our results show that there is an increase in circulating monocytes in tumor hosts; these monocytes exhibit a reduced expression of several myeloid differentiation markers such as CD115, F4/80, CD68 and CD11b. Moreover, downregulation of MHC II, CD62L and the proangiogenic marker Tie-2 are observed in these cells, whereas Gr-1 and Ly6C are upregulated. Furthermore, gene microarray analysis performed for the first time in blood monocytes from tumor hosts indicates that they express a mixture of pro-inflammatory and anti-inflammatory cytokines and chemokines. Interestingly, CCR2 and CX3CR1, which are crucial in monocyte definition as inflammatory or resident, respectively, are both upregulated. Importantly, complement proteins are enhanced whereas nitric oxide production is decreased and there is no measurable arginase activity detected in these cells. Collectively, our study represents the first comprehensive analysis of blood monocytes from tumor-bearing mice; we conclude that these cells are neither completely inflammatory nor suppressive and are less differentiated, similar to the macrophages they later become.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20811711     DOI: 10.3892/ijo_00000740

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  9 in total

Review 1.  Alterations in macrophages and monocytes from tumor-bearing mice: evidence of local and systemic immune impairment.

Authors:  Marta Torroella-Kouri; Dayron Rodríguez; Raul Caso
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

2.  Mammary tumors compromise time-of-day differences in hypothalamic gene expression and circadian behavior and physiology in mice.

Authors:  Kyle A Sullivan; Savannah R Bever; Daniel B McKim; Jonathan P Godbout; John F Sheridan; Karl Obrietan; Leah M Pyter
Journal:  Brain Behav Immun       Date:  2019-05-17       Impact factor: 7.217

3.  Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects.

Authors:  Alexander L Rakhmilevich; Mark J Baldeshwiler; Tyler J Van De Voort; Mildred A R Felder; Richard K Yang; Nicholas A Kalogriopoulos; David S Koslov; Nico Van Rooijen; Paul M Sondel
Journal:  Cancer Immunol Immunother       Date:  2012-03-06       Impact factor: 6.968

Review 4.  Oncogenic role of leptin and Notch interleukin-1 leptin crosstalk outcome in cancer.

Authors:  Crystal C Lipsey; Adriana Harbuzariu; Danielle Daley-Brown; Ruben R Gonzalez-Perez
Journal:  World J Methodol       Date:  2016-03-26

5.  Targeting myeloid regulatory cells in cancer by chemotherapeutic agents.

Authors:  Hiam Naiditch; Michael R Shurin; Galina V Shurin
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

6.  Tumor microenvironment profoundly modifies functional status of macrophages: peritoneal and tumor-associated macrophages are two very different subpopulations.

Authors:  Dayron Rodríguez; Risset Silvera; Roberto Carrio; Mehrdad Nadji; Raul Caso; Gracielena Rodríguez; Vijaya Iragavarapu-Charyulu; Marta Torroella-Kouri
Journal:  Cell Immunol       Date:  2013-06-19       Impact factor: 4.868

7.  Paracrine Interactions between Adipocytes and Tumor Cells Recruit and Modify Macrophages to the Mammary Tumor Microenvironment: The Role of Obesity and Inflammation in Breast Adipose Tissue.

Authors:  Ana M Santander; Omar Lopez-Ocejo; Olivia Casas; Thais Agostini; Lidia Sanchez; Eduardo Lamas-Basulto; Roberto Carrio; Margot P Cleary; Ruben R Gonzalez-Perez; Marta Torroella-Kouri
Journal:  Cancers (Basel)       Date:  2015-01-15       Impact factor: 6.639

Review 8.  Complement anaphylatoxins as immune regulators in cancer.

Authors:  Eli T Sayegh; Orin Bloch; Andrew T Parsa
Journal:  Cancer Med       Date:  2014-04-08       Impact factor: 4.452

9.  CD163+ tumor-associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytes.

Authors:  Rodrigo Nalio Ramos; Céline Rodriguez; Margaux Hubert; Maude Ardin; Isabelle Treilleux; Carola H Ries; Emilie Lavergne; Sylvie Chabaud; Amélie Colombe; Olivier Trédan; Henrique Gomes Guedes; Fábio Laginha; Wilfrid Richer; Eliane Piaggio; José Alexandre M Barbuto; Christophe Caux; Christine Ménétrier-Caux; Nathalie Bendriss-Vermare
Journal:  Clin Transl Immunology       Date:  2020-02-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.